Cognitive deficits are a core feature of schizophrenia, account for much of the impaired
functioning associated with the disorder and are not responsive to existing treatments. In this …

The neurodevelopmental and dopamine hypotheses are leading theories of the
pathoetiology of schizophrenia, but they were developed in isolation. However, since they …

Schizophrenia is a leading cause of global disability. Current pharmacotherapy for the
disease predominantly uses one mechanism—dopamine D2 receptor blockade—but often …

The NMDA-R hypofunction model of schizophrenia started with the clinical observation of
the precipitation of psychotic symptoms in patients with schizophrenia exposed to PCP or …

The negative symptoms of schizophrenia, which often appear earlier than any other
symptom, are prominent and clinically relevant in the majority of patients. As a result, interest …

The predominant inhibitory neurotransmitter in the brain, γ-aminobutyric acid (GABA), acts at
ionotropic GABAA receptors to counterbalance excitation and regulate neuronal firing …

Background: On the current psychopharmacological panorama, the variety of substances
able to provoke an episode of acute psychosis is rapidly increasing. Such psychotic …

Mental illness modeling is still a major challenge for scientists. Animal models of
schizophrenia are essential to gain a better understanding of the disease etiopathology and …

The discovery of ketamine as a rapid-acting antidepressant spurred significant research to
understand its underlying mechanisms of action and to identify other novel compounds that …

Introduction: Esketamine nasal spray received approval for treatment-resistant depression in
March 2019. Objective: Using the FDA Adverse Event Reporting System (FAERS) database …